Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Hat-Type Glasses Intervention in Phototherapy-Related Newborns

6 luglio 2026 aggiornato da: Dr. Hatice Dönmez, Karamanoğlu Mehmetbey University

The Effect of the Hat-Type Glasses Intervention Used in Phototherapy on Phototherapy Stay Duration, Comfort Level, and Parental Satisfaction

Aim : "This study aims to determine the effect of using a cap with protective eye goggles in term newborns undergoing phototherapy on the duration of phototherapy, the newborns' comfort level, and parental satisfaction."

Study Design:

This study has a randomized controlled, single-blind experimental design. Variables of the Study Dependent variables: Pulse and saturation values, Newborn Comfort Behavior Scale Score, bilirubin level, parental satisfaction level, duration of phototherapy.

Independent variables: Demographic variables related to parents and newborns, the hat-with-goggles intervention.

Limitations of the Study

  • The fact that the study data were collected from a single center constitutes a limitation.
  • The hat-with-goggles intervention can only be applied to infants in primary care settings and those placed in cot beds, which represents another limitation.

4.2. Research Question and Hypotheses H1.1: The hat-with-goggles intervention applied to newborns receiving phototherapy has an effect on newborns' comfort levels.

H1.2: The hat-with-goggles intervention applied to newborns receiving phototherapy has an effect on newborns' bilirubin levels.

H1.3: The hat-with-goggles intervention applied to newborns receiving phototherapy has an effect on the duration of phototherapy.

H1.4: The hat-with-goggles intervention applied to newborns receiving phototherapy has an effect on parental satisfaction levels.

Panoramica dello studio

Stato

Iscrizione su invito

Descrizione dettagliata

Population and Sample The population of the study will consist of newborns who are followed in the Neonatal Intensive Care Unit of Karaman Training and Research Hospital and receive phototherapy with a diagnosis of hyperbilirubinemia. The sample of the study will include the infants of parents who meet the inclusion criteria and voluntarily agree to participate in the study. The sample size was calculated using the G*Power 3.1.9.4 program. The results of a study investigating the effect of the smell of breast milk on the comfort level of newborns receiving phototherapy in a neonatal intensive care unit were used as a reference. With a significance level of 0.05, a 95% confidence interval, an effect size of 1.06 and a power of 95%, it was determined that each group should include 20 infants. Considering possible case losses during the research process, the sample size was increased by 12%, and it was planned to include 24 infants in each group.

Inclusion Criteria

  • Being a term newborn (38-42 gestational weeks)
  • Having an Apgar score of 7-10
  • Being hospitalized in a primary care setting and in a cot bed Exclusion Criteria
  • Hospitalization with a diagnosis of pathological jaundice
  • Presence of congenital anomalies in the newborn
  • Mothers having a condition that may prevent them from completing the questionnaire (such as language barriers) or having a communication impairment
  • Parents not wanting their newborn to participate in the study, or wishing to withdraw during the course of the study Withdrawal Criteria
  • After being included in the study, the newborn receives an additional diagnosis of any disease other than physiological jaundice
  • Infants who remain under phototherapy for less than 2 hours Randomization and Blinding Newborns who meet the inclusion criteria will be randomly assigned to two groups: the control group and the intervention group (hat-with-goggles application). Block randomization will be used to allocate participants to the control and intervention groups. Randomization will be stratified according to the variables "bilirubin level" and "sex." The selection of sex as a stratification variable is based on the literature, which reports that male sex is associated with hyperbilirubinemia during the neonatal period . Therefore, the sex variable was included in the stratification. Randomization was performed using the Research Randomizer program.

Data Sources and Data Collection Method The data of the study will be collected using the "Personal Data Collection Form," "Phototherapy Follow-up Chart," "Newborn Comfort Behavior Scale," and the "Parental Satisfaction Scale."

In Data Collection:

  • Personal Data Collection Form
  • Phototherapy Follow-up Chart
  • Newborn Comfort Behavior Scale
  • Parental Satisfaction Scale

DATA COLLECTION Hat-Integrated Eye Mask The hat-integrated eye mask is a material produced by combining a newborn beanie-made of 100% cotton and free of allergens-with a phototherapy eye mask. The phototherapy eye mask is made of medical-grade material and includes a neoprene eye pad that blocks 100% of harmful light to the eyes. It is designed to remain securely in place on the head without slipping and features adjustable Velcro straps to prevent displacement. It is manufactured from flexible, soft, latex-free carbon and/or other suitable materials that do not irritate the infant's skin.

The phototherapy eye mask used in the production of the hat-integrated eye mask will have the same technical specifications as the standard phototherapy mask routinely used in the clinic. Neoprene fabric is preferred in these masks because it does not allow the passage of light. In routine clinical use, no redness, allergic reactions, skin irritation, erythema, or itching have been reported. A phototherapy eye mask approved for clinical use by the Ministry of Health will be used. No alternative type of eye mask will be preferred in the production of the hat-integrated eye mask. Technical specifications required for procurement will match those of the standard phototherapy eye mask used in the control group.

Considering risks such as sweating, itching, and redness that may arise with prolonged use, newborns receiving phototherapy inside an incubator were excluded from the study. In line with the anticipated increase in comfort level and maternal satisfaction associated with the hat-integrated eye mask, multidisciplinary studies may support the development of material types specifically tailored for newborns receiving phototherapy in incubators.

Study data will be collected only from infants receiving phototherapy in cot beds. The hat-integrated eye masks will be produced by a tailor outside the hospital. All materials used in production will be chosen to allow sterilization. Accordingly, each hat-integrated eye mask must be sterilized before being applied to newborns for infection control purposes. The masks will be single-use only and will not be re-sterilized after use. The sterilization process will be conducted before application, and the masks will be discarded after the infant is discharged.

Intervention Group Newborns in the intervention group will be fitted with a hat-integrated eye mask. This hat-integrated eye mask is designed to prevent the phototherapy goggles from slipping during phototherapy and consists of a hat combined with an eye band. The application aims to prevent retinal damage that may occur in the newborn's eyes due to phototherapy light, and by reducing the effect of light passing through the head region on the pineal gland, it supports maintaining melatonin levels and increasing comfort.

For newborns in the intervention group, before applying the hat-integrated eye mask during hospital admission, they will be placed in an open crib and their vital signs will be assessed using a pulse oximeter. To prepare the newborn for phototherapy, clothing will be removed, the cleanliness of the diaper will be ensured, and the saturation probe will be attached. Afterward, the hat-with-goggles will be placed on the newborn, and phototherapy will be initiated. Vital signs will be assessed while the newborn is in the mother's arms before phototherapy, at minute 0 (immediately before starting phototherapy), at the 60th minute, and at the 24th hour. Newborn comfort behaviors will be assessed at these same time points by two experts.

According to the literature, newborns require 14-17 hours of sleep per day, which is divided into 4 or 5 periods. Each period includes awake intervals of 40-80 minutes. Considering this information, the variability of phototherapy duration among newborns, and the working principles of the clinic, the timing of vital sign assessments and comfort measurements was determined as before phototherapy in the mother's arms, at minute 0 (immediately before phototherapy), at the 60th minute, and at the 24th hour.

The time and reasons for discontinuation of phototherapy will be recorded by the researcher during the phototherapy process. The satisfaction levels of mothers in the intervention group will be evaluated after phototherapy (when phototherapy is discontinued).

________________________________________ Control Group Newborns in the control group will wear the standard phototherapy eye mask routinely used in the clinic. For newborns in this group, before placing the standard eye mask during hospital admission, they will be placed in an open crib and their vital signs will be assessed using a pulse oximeter. To prepare the newborn for phototherapy, clothing will be removed, the cleanliness of the diaper will be checked, and the saturation probe will be placed. Then, the routine phototherapy eye mask will be applied, and phototherapy will begin.

Vital signs will be assessed before phototherapy, at the 60th minute, and at the 24th hour. Newborn comfort behaviors will be assessed by two experts before phototherapy in the mother's arms, at the initiation of phototherapy, at the 60th minute, and at the 24th hour. The time and reasons for discontinuation of phototherapy will be recorded by the researcher during the phototherapy procedure. The satisfaction levels of mothers in the control group will also be evaluated after phototherapy (when phototherapy is discontinued).

Data Analysis The statistical analysis of the study will be conducted using IBM SPSS Statistics Version 23, with a significance level of p<0.05. The normality of data distribution will be assessed using the Shapiro-Wilk test. Parametric analyses (t-test and ANOVA) will be performed for normally distributed data, whereas non-parametric analyses (Mann-Whitney U and Kruskal-Wallis tests) will be used for data not meeting normality assumptions. Repeated measures will be analyzed using analysis of variance. Cohen's Kappa analysis will be used to evaluate inter-rater agreement between the two observers. Analysis results will be presented as mean, standard deviation, and median (1st and 3rd quartiles) for quantitative data, and as frequency (percentage) for categorical data.

________________________________________ Ethical Considerations To conduct the study, permission to use the scales-previously validated and tested for reliability in Turkish-will first be obtained from the original authors via email. Mothers of newborns who meet the inclusion criteria will be informed about the study, and written informed consent will be obtained from those who agree to participate. Since the study involves human subjects, the ethical principles of "Informed Consent," "Voluntariness," and "Confidentiality" will be strictly observed. Ethical approval for the study will be obtained from the Scientific Research and Publication Ethics Committee of Karamanoğlu Mehmetbey University, Faculty of Health Sciences. Additionally, institutional permission will be obtained to conduct the study in the Neonatal Intensive Care Unit of Karaman Training and Research Hospital.

Tipo di studio

Interventistico

Iscrizione (Stimato)

24

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • Karaman, Turchia (Türkiye)
        • Karaman Training and Research Hospital
      • Karaman, Turchia (Türkiye)
        • Karamanoğlu Mehmetbey Üniversitesi

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Bambino

Accetta volontari sani

No

Descrizione

Inclusion Criteria:

  • Inclusion Criteria

    • Being a term newborn (38-42 gestational weeks)
    • Having an Apgar score of 7-10
    • Being hospitalized in a primary care setting and in a cot bed

Exclusion Criteria:

  • Hospitalization with a diagnosis of pathological jaundice

    • Presence of congenital anomalies in the newborn
    • Mothers having a condition that may prevent them from completing the questionnaire (such as language barriers) or having a communication impairment
    • Parents not wanting their newborn to participate in the study, or wishing to withdraw during the course of the study

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Terapia di supporto
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Hat-with-Goggles Group
Newborns receiving phototherapy will use the hat-with-goggles device during phototherapy treatment.
The conventional eye patch routinely used during phototherapy in newborns with hyperbilirubinemia.
Altri nomi:
  • Standard Eye Patch
Nessun intervento: Active Comparator
Newborns receiving phototherapy will use the standard eye patch routinely applied during phototherapy.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Newborn Comfort Level
Lasso di tempo: Baseline, 60 minutes, and 24 hours after the start of phototherapy.
Newborn comfort will be assessed using the Neonatal Comfort Behavior Scale. The comfort assessment in the Neonatal Comfort Behavior Scale consists of six parameters: wakefulness, calmness/agitation, respiratory response (assessed only in mechanically ventilated newborns), crying, body movements, facial tension, and muscle tone. In newborns receiving mechanical ventilation, the "Respiratory Response" component is considered, while in those not receiving mechanical ventilation, the "Crying" component is considered. Each parameter is on a five-point Likert scale and is scored between 1 and 5. The comfort assessment in this section is done based on the total score. A minimum of 6 and a maximum of 30 points can be obtained from the NCT. A total score between 6-13 means the newborn is comfortable, and a score between 14-30 means the newborn is not comfortable.Comfort scores will be recorded at baseline, 60 minutes after the start of phototherapy, and at 24 hours of phototherapy.
Baseline, 60 minutes, and 24 hours after the start of phototherapy.

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Serum Bilirubin Level Monitoring Chart
Lasso di tempo: Baseline and completion of phototherapy (up to 24 hours)
Measurement of serum bilirubin levels during phototherapy treatment.Serum bilirubin levels of newborns will be measured during phototherapy treatment. Changes (decreases/increases) in these measurements will be monitored. Changes in serum bilirubin levels will be statistically compared between the group receiving glasses and the control group.
Baseline and completion of phototherapy (up to 24 hours)
PHOTOTHERAPY TRACKING CHART
Lasso di tempo: At completion of phototherapy (up to 24 hours)
The duration of phototherapy treatment will be recorded in hours, and this output will be considered the total phototherapy time. Interruptions to phototherapy will be deducted from the total time. Reasons for interruptions will be recorded. Phototherapy duration will be statistically compared between the group using glasses and a control group. A decrease in phototherapy duration is expected in cases of better compliance with phototherapy and less discontinuation.
At completion of phototherapy (up to 24 hours)
Parent Satisfaction Scale
Lasso di tempo: At completion of phototherapy (up to 24 hours)
Parental satisfaction with the eye protection method used during phototherapy (eye mask/routine application) will be evaluated (for reasons such as the newborn's eye mask coming off their eyes or the newborn becoming restless during phototherapy). The evaluation will be done using a scale of 1-10, where 1 indicates low satisfaction and 10 indicates high satisfaction.
At completion of phototherapy (up to 24 hours)

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

20 agosto 2025

Completamento primario (Stimato)

15 luglio 2026

Completamento dello studio (Stimato)

30 agosto 2026

Date di iscrizione allo studio

Primo inviato

8 giugno 2026

Primo inviato che soddisfa i criteri di controllo qualità

6 luglio 2026

Primo Inserito (Effettivo)

8 luglio 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

8 luglio 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

6 luglio 2026

Ultimo verificato

1 luglio 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Descrizione del piano IPD

Individual participant data (IPD) will not be shared because the informed consent obtained from participants did not include permission for public data sharing, and data confidentiality and participant privacy will be maintained in accordance with institutional and ethical requirements.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

3
Sottoscrivi